NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Recruiting now · Phase 3 · Has a placebo group
Conditions studied: Major Depressive Disorder
In brief
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Key facts
- Study ID
- NCT06911112
- Run by
- Neurocrine Biosciences
- People needed
- 200
- Starts
- 2025-03-31
- Expected to finish
- 2027-07-01
- Last updated by the study team
- 2025-12-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Neurocrine Clinical Site — Huntsville, Alabama, United States (enrolling)
- Neurocrine Clinical Site — Glendale, California, United States (enrolling)
- Neurocrine Clinical Site — Irvine, California, United States (enrolling)
- Neurocrine Clinical Site — Miami, Florida, United States (enrolling)
- Neurocrine Clinical Site — Tampa, Florida, United States (enrolling)
- Neurocrine Clinical Site — Atlanta, Georgia, United States (enrolling)
- Neurocrine Clinical Site — Boston, Massachusetts, United States (enrolling)
- Neurocrine Clinical Site — Saint Charles, Missouri, United States (enrolling)
- Neurocrine Clinical Site — The Bronx, New York, United States (enrolling)
- Neurocrine Clinical Site — Mason, Ohio, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.